Pages that link to "Q37783616"
Jump to navigation
Jump to search
The following pages link to Combretastatin A4 Phosphate: A Novel Vascular Disrupting Agent (Q37783616):
Displaying 21 items.
- Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site (Q28067375) (← links)
- Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties (Q31024172) (← links)
- A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment (Q34765364) (← links)
- Near-IR Light-Mediated Cleavage of Antibody-Drug Conjugates Using Cyanine Photocages (Q36551221) (← links)
- Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications (Q36609881) (← links)
- The anti-angiogenic effect and novel mechanisms of action of Combretastatin A-4 (Q37034926) (← links)
- ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF/VEGFR-2 signaling (Q37109919) (← links)
- Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy (Q37536654) (← links)
- Indole-fused benzooxazepines: a new structural class of anticancer agents. (Q37701753) (← links)
- Contemporary Challenges in the Design of Topoisomerase II Inhibitors for Cancer Chemotherapy (Q37991381) (← links)
- Medicinal applications of (benz)imidazole- and indole-based macrocycles (Q38709166) (← links)
- Dynamic contrast enhanced fluorescent molecular imaging of vascular disruption induced by combretastatin-A4P in tumor xenografts (Q38976012) (← links)
- Visible Light Controlled Release of Anticancer Drug through Double Activation of Prodrug (Q39769440) (← links)
- Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review. (Q41258130) (← links)
- NDRG1 inhibition sensitizes osteosarcoma cells to combretastatin A-4 through targeting autophagy (Q41911962) (← links)
- CuI/1,10-phen/PEG promoted decarboxylation of 2,3-diarylacrylic acids: synthesis of stilbenes under neutral and microwave conditions with an in situ generated recyclable catalyst (Q44864691) (← links)
- The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells (Q49302678) (← links)
- Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cells (Q49824712) (← links)
- Drug-Clinical Agent Molecular Hybrid: Synthesis of Diaryl(trifluoromethyl)pyrazoles as Tubulin Targeting Anticancer Agents. (Q55654489) (← links)
- Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy (Q91737303) (← links)
- Combretastatin-Inspired Heterocycles as Antitubulin Anticancer Agents (Q92939175) (← links)